Aging is the main risk for neurodegenerative disorders like Alzheimer’s disease. In this short review, I will comment on how delaying brain aging through the addition of Yamanaka Factors or small compounds that bind to the folate receptor alpha, which promote the expression of the Yamanaka Factors or by the decrease tau levels in brain cells from older subjects could serve as strategies to prevent Alzheimer’s disease.
PerryG, AvilaJ, EspeyMG, et al. Biochemistry of neurodegeneration. Science2001; 291: 595–597.
2.
ZhuX, AvilaJ, PerryG, et al. Treating the lesions, not the disease. Am J Pathol2007; 170: 1457–1459.
3.
AhadiS, ZhouW, Schussler-Fiorenza RoseSM, et al. Personal aging markers and ageotypes revealed by deep longitudinal profiling. Nat Med2020; 26: 83–90.
4.
OhHS, RutledgeJ, NachunD, et al. Organ aging signatures in the plasma proteome track health and disease. Nature2023; 624: 164–172.
5.
AvilaJ, LucasJJ, PerezM, et al. Role of tau protein in both physiological and pathological conditions. Physiol Rev2004; 84: 361–384.
6.
BueeL, BussiereT, Buee-ScherrerV, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev2000; 33: 95–130.
7.
GoedertM, GhettiB and SpillantiniMG. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med2012; 2: a006254.
8.
IqbalK, LiuF and GongCX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol2016; 12: 15–27.
9.
IttnerLM and GotzJ. Amyloid-beta and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci2011; 12: 65–72.
10.
LeeVM, GoedertM and TrojanowskiJQ. Neurodegenerative tauopathies. Annu Rev Neurosci2001; 24: 1121–1159.
11.
Anton-FernandezA, Valles-SaizL, AvilaJ, et al. Neuronal nuclear tau and neurodegeneration. Neuroscience2023; 518: 178–184.
12.
GilL, FedericoC, PinedoF, et al. Aging dependent effect of nuclear tau. Brain Res2017; 1677: 129–137.
13.
GuoC, JeongHH, HsiehYC, et al. Tau activates transposable elements in Alzheimer’s disease. Cell Rep2018; 23: 2874–2880.
14.
LiuC and GotzJ. Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLoS One2013; 8: e84849.
15.
RitterML, AvilaJ, Garcia-EscuderoV, et al. Frontotemporal dementia-associated N279K tau mutation localizes at the nuclear compartment. Front Cell Neurosci2018; 12: 202.
16.
MansurogluZ, Benhelli-MokraniH, MarcatoV, et al. Loss of tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin. Sci Rep2016; 6: 33047.
17.
SjobergMK, ShestakovaE, MansurogluZ, et al. Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J Cell Sci2006; 119: 2025–2034.
18.
HanYN, LiY, XiaSQ, et al. PIWI proteins and PIWI-interacting RNA: emerging roles in cancer. Cell Physiol Biochem2017; 44: 1–20.
19.
Valles-SaizL, AvilaJ and HernandezF. Lamivudine (3TC), a nucleoside reverse transcriptase inhibitor, prevents the neuropathological alterations present in mutant tau transgenic mice. Int J Mol Sci2023; 24: 11144.
20.
VilleponteauB. The heterochromatin loss model of aging. Exp Gerontol1997; 32: 383–394.
21.
Monroy-RamirezHC, Basurto-IslasG, MenaR, et al. Alterations in the nuclear architecture produced by the overexpression of tau protein in neuroblastoma cells. J Alzheimers Dis2013; 36: 503–520.
22.
DeVosSL, MillerRL, SchochKM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med2017; 9: eaag0481.
23.
ZhangZY, HarischandraDS, WangR, et al. TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease. Science2023; 381: eadd6696.
24.
ZhuG, HarischandraDS, GhaisasS, et al. TRIM11 prevents and reverses protein aggregation and rescues a mouse model of Parkinson’s disease. Cell Rep2020; 33: 108418.
25.
FuY, ZhangB and LiuJ. Tripartite motif-containing protein 11 (TRIM11): a novel weapon against Alzheimer’s disease. Signal Transduct Target Ther2024; 9: 3.
26.
CongdonEE and SigurdssonEM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol2018; 14: 399–415.
27.
GonzalesMM, GarbarinoVR, KautzTF, et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nat Med2023; 29: 2481–2488.
28.
ZhuY, TchkoniaT, PirtskhalavaT, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell2015; 14: 644–658.
29.
BirchJ and GilJ. Senescence and the SASP: many therapeutic avenues. Genes Dev2020; 34: 1565–1576.
30.
ChildsBG, GluscevicM, BakerDJ, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov2017; 16: 718–735.
31.
Melo Dos SantosLS, Trombetta-LimaM, EggenB, et al. Cellular senescence in brain aging and neurodegeneration. Ageing Res Rev2024; 93: 102141.
32.
HouY, DanX, BabbarM, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol2019; 15: 565–581.
33.
HorvathS and RajK. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet2018; 19: 371–384.
34.
Lopez-OtinC, BlascoMA, PartridgeL, et al. The hallmarks of aging. Cell2013; 153: 1194–1217.
35.
Lopez-OtinC, BlascoMA, PartridgeL, et al. Hallmarks of aging: An expanding universe. Cell2023; 186: 243–278.
36.
YangJH, HayanoM, GriffinPT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell2023; 186: 305–326e327.
37.
RamchandaniS, BhattacharyaSK, CervoniN, et al. DNA methylation is a reversible biological signal. Proc Natl Acad Sci U S A1999; 96: 6107–6112.
38.
BenayounBA, PollinaEA and BrunetA. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat Rev Mol Cell Biol2015; 16: 593–610.
39.
SenP, ShahPP, NativioR, et al. Epigenetic mechanisms of longevity and aging. Cell2016; 166: 822–839.
40.
TakahashiK and YamanakaS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006; 126: 663–676.
41.
OcampoA, ReddyP, Martinez-RedondoP, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell2016; 167: 1719–1733e1712.
42.
AbadM, MosteiroL, PantojaC, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature2013; 502: 340–345.
43.
Moreno-JimenezEP, Flor-GarciaM, Terreros-RoncalJ, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. Nat Med2019; 25: 554–560.
44.
KimJ, LengnerCJ, KirakO, et al. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factors. Stem Cells2011; 29: 992–1000.
45.
Rodriguez-MatellanA, AlcazarN, HernandezF, et al. In vivo reprogramming ameliorates aging features in dentate gyrus cells and improves memory in mice. Stem Cell Reports2020; 15: 1056–1066.
46.
Hernandez-BenitezR, WangC, ShiL, et al. Intervention with metabolites emulating endogenous cell transitions accelerates muscle regeneration in young and aged mice. Cell Rep Med2024; 5: 101449.
47.
KimY, JeongJ and ChoiD. Small-molecule-mediated reprogramming: a silver lining for regenerative medicine. Exp Mol Med2020; 52: 213–226.
48.
LiX, XuJ and DengH. Small molecule-induced cellular fate reprogramming: promising road leading to Rome. Curr Opin Genet Dev2018; 52: 29–35.
49.
BoshnjakuV, ShimKW, TsurubuchiT, et al. Nuclear localization of folate receptor alpha: a new role as a transcription factor. Sci Rep2012; 2: 980.
50.
Anton-FernandezA, CuadrosR, Peinado-CahucholaR, et al. Role of folate receptor alpha in the partial rejuvenation of dentate gyrus cells: Improvement of cognitive function in 21-month-old aged mice. Sci Rep2024; 14: 6915.
51.
MohantyV, ShahA, AllenderE, et al. Folate receptor alpha upregulates Oct4, Sox2 and Klf4 and downregulates miR-138 and miR-let-7 in cranial neural crest cells. Stem Cells2016; 34: 2721–2732.
52.
UhlenM, FagerbergL, HallstromBM, et al. Proteomics. Tissue-based map of the human proteome. Science2015; 347: 1260419.
53.
FioravantiM, FerrarioE, MassaiaM, et al. Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits. Arch Gerontol Geriatr1998; 26: 1–13.
54.
CummingsJ, ScheltensP, McKeithI, et al. Effect size analyses of souvenaid in patients with Alzheimer’s disease. J Alzheimers Dis2017; 55: 1131–1139.
55.
FieldMS, KamyninaE, ChonJ, et al. Nuclear folate metabolism. Annu Rev Nutr2018; 38: 219–243.
56.
ZhengY and CantleyLC. Toward a better understanding of folate metabolism in health and disease. J Exp Med2019; 216: 253–266.
57.
Hulin-CurtisSL, DaviesJA, NesticD, et al. Identification of folate receptor alpha (FRalpha) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Ther2020; 27: 785–798.
